Two products from Lai Mei Pharmaceutical, a subsidiary of Zhongheng Group, have been selected for the 2025 Beijing Municipal Pharmaceutical Collection.

According to the information from Zhongheng Group, the Beijing Municipal Medical Security Bureau recently officially announced the successful selection results of the "2025 Beijing Drug Centralized Volume Procurement Project". Two products from LaiMei Pharmaceutical, a subsidiary of Zhongheng Group, including Hydrochloride Clinamycin Injection and Calcium Heparin for Injection, were successfully selected. It is reported that this Beijing drug centralized volume procurement involved a total of 901 selected products from 360 manufacturing enterprises, with the procurement form mainly focusing on "volume linkage".